Skip to main content
Search
Main content
Nature communications
Published

ASC specks as a single-molecule fluid biomarker of inflammation in neurodegenerative diseases

Authors

Evgeniia Lobanova, Yu P Zhang, Derya Emin, Jack Brelstaff, Lakmini Kahanawita, Maura Malpetti, Annelies Quaegebeur, Kathy Triantafilou, Martha Triantafilou, Henrik Zetterberg, James B Rowe, Caroline H Williams-Gray, Clare Elizabeth Bryant, David Klenerman

Abstract

Nat Commun. 2024 Nov 11;15(1):9690. doi: 10.1038/s41467-024-53547-0.

ABSTRACT

Immunotherapeutic strategies for Alzheimer's and Parkinson's disease would be facilitated by better measures of inflammation. Here we established an ultra-sensitive single-molecule pull-down immunoassay combined with direct stochastic optical reconstruction microscopy (dSTORM) to measure the number, size and shape of individual extracellular inflammasome ASC specks. We assayed human post-mortem brain, serum and cerebrospinal fluid of patients with Parkinson's and Alzheimer's as well as healthy elderly. The number of ASC specks increased and showed altered morphology in the blood of early-stage Parkinson's and Alzheimer's patients compared to controls, mimicking those found in the brain and cerebrospinal fluid. In serum samples we also measured the number of Aβ, p-tau and α-syn aggregates and formed a composite biomarker of (ASC + p-tau)/Aβ and (ASC + α-syn)/Aβ ratios that distinguished age-matched healthy controls from patients with early-stage Alzheimer's with AUC of 92% and early-stage Parkinson's with AUC of 97%. Our findings confirm ASC specks as a fluid candidate biomarker of inflammation for neurodegenerative diseases with blood being the main focus for further development as convenient sample for diagnostics and clinical trials.

PMID:39528447 | PMC:PMC11555386 | DOI:10.1038/s41467-024-53547-0

UK DRI Authors

Maura Malpetti profile

Dr Maura Malpetti

Emerging Leader

Using specialist brain scans and novel blood tests to measure inflammation and accelerate the development of new treatments

Dr Maura Malpetti
Profile picture of Henrik Zetterberg

Prof Henrik Zetterberg

Group Leader

Pioneering the development of fluid biomarkers for dementia

Prof Henrik Zetterberg
David Klenerman

Prof Sir David Klenerman

Group Leader

Determining how protein clumps form, damage the brain and change as the different neurodegenerative diseases develop to know which ones to target for therapies

Prof Sir David Klenerman